-
Positive results from two prostate cancer trials
-
Phase 2 trial design gaining momentum
-
Investigational New Drug Application to be submitted to FDA in Q3 2019
-
Pipeline developing based on drug discovery program
-
Board changes underpinning growth
-
Successful fundraising completed in July intended to fund Company through to a proposed US Listing
Sydney, 29 July 2019: Noxopharm Limited (ASX: NOX) (‘Noxopharm’ or the ‘Company’) today releases its Appendix 4C for the quarter ended 30 June 2019, as well as providing guidance for the next 12 months. This report is for the Noxopharm Group covering both Noxopharm Limited and its majority-owned subsidiary, Nyrada Inc.
For further information please download the attached PDF:
Download this document
